Treatment of heart failure with reduced ejection fraction

Background: Heart failure with reduced ejection fraction (HFrEF) is a syndrome consisting of typical symptoms and/or signs heart (HF) due to left ventricular systolic dysfunction (ejection ≤40%) caused by various underlying cardiac diseases. We report conventional and recently established pharmacologic nonpharmacologic treatments HFrEF in this review article.Current Concepts: So far, have been proven beneficial reducing HFassociated hospitalization or death. The mainstay the renin-angiotensin-aldosterone system inhibitors, which are sympathetic nervous blockers on top diuretics relieve systemic pulmonary congestion. Recently, new treatment targets for natriuretic peptide sodium-glucose cotransporter emerged HFrEF, allowing use these novel drugs addition optimal medications. Device therapies, such as implantable cardioverter-defibrillator resynchronization therapy, can improve outcome special population. transplantation final patients advanced HF. However, limitation donor pool, mechanical circulatory support necessary.Discussion Conclusion: Current guidelines recommend using four pillars medications including angiotensin-converting enzyme inhibitors (angiotensin-neprilysin angiotensin receptor blockers), beta-blockers, mineralocorticoid antagonists, inhibitors. Appropriate device support, enhance survival HF patients. Balanced treatment, newer necessary.